Institutional shares held 24.7 Million
299K calls
97.6K puts
Total value of holdings $3.55B
$42.9M calls
$14M puts
Market Cap $3.69B
25,664,300 Shares Out.
Institutional ownership 96.33%
# of Institutions 326


Latest Institutional Activity in KRYS

Top Purchases

Q2 2025
Goldman Sachs Group Inc Shares Held: 530K ($76.2M)
Q2 2025
Norges Bank Shares Held: 283K ($40.6M)
Q2 2025
First Trust Advisors LP Shares Held: 222K ($31.9M)
Q2 2025
Readystate Asset Management LP Shares Held: 148K ($21.3M)
Q2 2025
State Street Corp Shares Held: 1.36M ($195M)

Top Sells

Q2 2025
Ubs Asset Management Americas Inc Shares Held: 234K ($33.7M)
Q2 2025
Invesco Ltd. Shares Held: 70.9K ($10.2M)
Q2 2025
Price T Rowe Associates Inc Shares Held: 261K ($37.5M)
Q2 2025
Redmile Group, LLC Shares Held: 663K ($95.3M)
Q2 2025
Woodline Partners LP Shares Held: 151K ($21.6M)

About KRYS

Krystal Biotech, Inc., a clinical stage biotechnology company, engages in the field of redosable gene therapy to treat serious rare diseases in the United States. Its lead product candidate is beremagene geperpavec (B-VEC), which is in Phase III clinical study to treat dystrophic epidermolysis bullosa. The company is also involved in developing KB105 that is in Phase I/II clinical study for treating patients with deficient autosomal recessive congenital ichthyosis; KB301, which is in Phase I/II clinical stage for treating wrinkles and other presentations of aged or damaged skin; KB407 that is in preclinical stage for cystic fibrosis; and KB104, which is in preclinical stage for netherton syndrome. Its discovery stage product candidates include KB5xx for treating chronic skin diseases, KB3xx to treat aesthetic skin conditions, and KB3xx product. Krystal Biotech, Inc. was founded in 2015 and is headquartered in Pittsburgh, Pennsylvania.


Insider Transactions at KRYS

Insider Transaction List

View all
Date Insider Transaction Ownership Type Shares Traded Value / Price
View All Transactions

Last 12 Months Summary

Buy / Acquisition
168K Shares
From 3 Insiders
Exercise of conversion of derivative security 168K shares
Sell / Disposition
502K Shares
From 7 Insiders
Payment of exercise price or tax liability 95.8K shares
Open market or private sale 401K shares
Bona fide gift 5K shares

Track Institutional and Insider Activities on KRYS

Follow Krystal Biotech, Inc. and customize your updates to receive the information that matters most to you.

Institutional Portfolio Updates

Receive a notification when an Institution or Guru buys or sells KRYS shares.

Notify only if

Insider Trading

Get notified when an Krystal Biotech, Inc. insider buys or sells KRYS shares.

Notify only if

News

Receive news related to Krystal Biotech, Inc.

Track Activities on KRYS